Skip to main content

Pharmacotherapy: Diabetes Mellitus-Insulin Therapy!

PHARMACOTHERAPY

Medications classifications include:

  1.  Sulfonyl Urea's
  2. Nonsylfonylurea Secretagogues (a-Glinides)
  3. Biguanides
  4. Thiazolidinediones
  5. a-Glucosidase Inhibitors
  6. Dipeptidyl Peptidase-4 Inhibitors (Gliptins)
  7. Sodium-glucose co-transporter (SGLT) Inhibitors 
  8. Central-Acting Dopamine Agonists
  9. Bile Acid Sequestrants
  10. Insulin therapy

10. INSULIN THERAPY

  • Insulin is used for the primary treatment in T1DM.
  • Insulin is used in all types of DM and has no specific maximum dose.
  • Insulin is the primary treatment in T1DM, and injected amylin can be added to decrease fluctuations in blood glucose levels.
  • Insulin is available in various formulations. Most formulations are available as U-100, indicating a concentrations of 100unit/mL.

Types:

  • Insulin is divided into two main classes:

                1. Basal Insulin                                                                             2. Bolus insulin

Storage:

  • Insulin is typically refrigerated, and most vials are good for 28 days at room temperature
  • Insulin detemir can be stored at room temperature for 42 days.

Route of Administration:

  • Most common route of administration is Subcutaneous injection using a syringe or a pen device.
  • Patients should be educated to rotate their site of injection administrations to minimize lipohypertrophy(a buildup of fat that decreases or prevents proper insulin absorption).
  • The fastest absorption occurs in the Abdomen and the slowest in the buttocks.

Insulin Devices:

  • Insulin syringes are distinguished according to the syringe capacity, syringe markings, needle Guage and length.
  • Insulin pens are self-contained systems of insulin delivery. The primary advantage of Pen system is that patients do not have to draw up the dose from the Insulin vial.


*Only Insulin that can be administered IV -- Regular or Human Insulin*

*Rapid Acting Insulins are-- Insulin Aspart, Insulin Glulisine, Insulin Lispro*


1.BOLUS INSULIN (covers insulin response to meals):

Regular Insulin:

  • Regular insulin is unmodified crystalline insulin commonly referred to as Neutral or Human Insulin.
  • It is a clear solution that has relatively short onset and duration of action and is designed to cover insulin response to meals.
  • On SC injection, Regular insulin forms small aggregates called Hexamers that undergo conversion to Dimers followed by Monomers before systemic absorption can occur.
  • Patients should be counselled to inject insulin SC 30 minutes before consuming a meal.
  • It is the only insulin administered IV.
  • Three rapidly acting insulins approved by United States are Aspart, Glulisine, and Lispro. Substitution of one or two amino acids in regular insulin results in the unique pharmacokinetic properties characteristics of these agents.

2.Basal Insulin (Covers insulin response in between the meals and overnight):

Intermediate Duration Insulin:

  • Neutral Protamine Hagedorn, better known as NPH insulin is prepared by a process in which protamine is conjugated with regular insulin, rendering a product with delayed onset but extended duration of action and is designed to cover insulin requirements between meals and/or overnight.
  • With the advent of the long-acting insulins, NPH insulin use has been declined because of the inability to predict accurately when peak effects occur and a duration of action less then 24hr.
  • Additionally, Protamine is a foreign protein that may increase the possibility of an allergic reaction.
  • NPH insulin can be mixed with regular insulin and used immediately or stored for future use up to 1 month at room temperature or 3 months in refrigerator.
  • NPH can be mixed with either Aspart or Lispro insulins, but it must be injected immediately after mixing.
  • Whenever mixing insulin products with NPH, the shorter acting insulin should be drawn into the syringe first.

Long-duration Insulin:

Glargine and Detemir are designed once daily dosing basal Insulin.

  • Insulin Glargine differs from regular insulin by three amino acids, resulting in a low solubility at physiologic pH.
  • Detemir binds to albumin in the plasma, which gives it sustained action.
  • Neither Glargine nor Detemir can be administered IV or mixed with other insulin products.
  • Both Glargine and Detemir have been shown to produce slower, more prolonged absorption and a relatively constant concentration over 24hr as compared with NPH.

Combination Insulin Products:

  • NPH is available in combinations of 70/30 (70% NPH & 30% Regular insulin). and 50/50 (50% NPH & 50% Regular insulin).
  • Two short-acting insulin analog mixtures are also available;

  1. Humalog mix 75/25 contains 75% insulin lispro protamine suspension and 25% insulin lispro.
  2. Novolog mix 70/30 contains 70% insulin aspart protamine suspension and 30% insulin aspart.


Comments

Popular posts from this blog

Diabetes Mellitus: Types!

TYPES OF DIABETES MELLITUS 1. TYPE1 DM Type 1 DM is usually diagnosed before age 30 years, but it can develop at any age. T1DM is an autoimmune disease in which insulin producing B-cells are destroyed. The presence of Human Leucocyte Antigens (HLAs ) is associated with the development of T1DM. In addition, these individuals often develop Islet cell antibodies , Insulin Autoantibodies or Glutamic Acid decarboxylase autoantibodies . At the time of development of diagnosis of T1DM, it is usually believed that most of the patients have 80-90%loss of beta cells. The remaining beta cells function at the diagnosis creates a " HONEYMOON PERIOD" during which the blood glucose levels are easier to control, and smaller amounts of insulin are required. after this, the remaining beta cells function is completely lost, and the patients become completely deficient of insulin and hence require exogenous insulin.  2. TYPE1.5 DM:  Also referred as Latent autoimmune diabetes in Adults (LAD)

Diabetes Mellitus: Pharmacotherapy- Gliptins and a-Glycoside Inhibitors!

  PHARMACOTHERAPY:  Medications classifications include:  Sulfonyl Urea's Nonsylfonylurea Secretagogues (a-Glinides) Biguanides Thiazolidinediones a-Glucosidase Inhibitors Dipeptidyl Peptidase-4 Inhibitors (Gliptins) Sodium-glucose co-transporter (SGLT) Inhibitors  Central-Acting Dopamine Agonists Bile Acid Sequestrants Insulin therapy 5. a-GLUCOSIDASE INHIBITORS Acarbose and Miglitol are a-glucosidase inhibitors currently approved in the United States. Mechanism of Action: An enzyme that is along the brush border of the intestine cells called a-glucosidase; breaks down the complex carbohydrates into simple sugars, resulting in absorption. The a-glucosidase inhibitors work by delaying the absorption of carbohydrates from the intestinal tract, which reduces the rise in postprandial glucose levels. Therapy: As a monotherapy , a-glucosidase inhibitors primarily reduce post-prandial glucose excursions.  Clinical Use: FPG concentrations have been decreased by 40-50mg/dL and A1c level

GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD)!

MANAGEMENT OF GASTRO-ESOPHAGEAL REFLUX DISEASE  "GERD refers to the endoscopically determined esophagitis or endoscopy-negative reflux disease" . "GERD is the term used to describe any symptomatic clinical condition or histopathological alteration resulting from episodes of reflux of acid, pepsin and occasionally, bile into the esophagus from the stomach". Patients with uninvestigated "reflux-like" symptoms should be managed as patients with uninvestigated dyspepsia. There is currently no evidence that H.pylori should be investigated in patients with GERD. Symptoms: Heartburn is the characteristic symptom of GERD. Acid regurgitation Dysphagia Belching Upper abdominal discomfort Bloating and postprandial fullness Chest pain Hoarseness Cough Complications include: Esophageal ulceration Formation of specialized columnar-lined esophagus at the gastro-esophageal junction known as Barretts Esophagus . Mechanism of Acid Reflux: The mechanism of acid reflux is mu